1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022


Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Fanapt (iloperidone) is a D2/5-HT2A antagonist, but also has an increased activity at serotonin 5-HT7 receptors, which are believed to modulate striatal and cortical DA function. With enhanced antagonistic activity at a1 receptor sites and low activity on histamine H1 receptors, Fanapt has been associated with an issue of orthostatic hypotension (due to a1 blockade) rather than weight gain and sedation like other agents within its class.


- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fanapt including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fanapt for the top two countries from 2012 to 2022.
- Sales information covered for the US and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fanapt performance
- Obtain sales forecast for Fanapt from 2012-2022 in the top two countries (the US and Japan)

Table Of Contents

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Diagnosis 14
4.1.1 Subjective Assessments 15
4.1.2 Disease Subtypes 16
4.2 Treatment Overview 19
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 21
4.2.2 Maintenance Treatment of Schizophrenia 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Fanapt (iloperidone) 26
6.1 Overview 26
6.2 Efficacy as a Short-Term Maintenance Treatment 26
6.3 Safety 27
6.4 SWOT Analysis 28
6.5 Forecast 28
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 32
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 Diagnosis and Treatment Rates 33
7.4.2 Adherence Rates 34
7.4.3 General Pricing Assumptions 34
7.4.4 Drug Assumptions 35
7.4.5 Generic Erosion 36
7.5 Key Opinion Leaders 37
7.6 About the Authors 38
7.6.1 Author 38
7.6.2 Reviewers 38
7.6.3 Global Head of Healthcare 39
7.7 About GlobalData 40
7.8 Disclaimer 40

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 13
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 16
Table 3: Development-Based Classification of Antipsychotic Drugs 19
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 20
Table 5: Guidelines for the Treatment of Schizophrenia 21
Table 6: Leading Branded Treatments for Schizophrenia, 2013 25
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 25
Table 8: Product Profile - Fanapt 26
Table 9: Fanapt SWOT Analysis, 2014 28
Table 10: Global Sales Forecast ($m) for Fanapt, 2012-2022 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Anti-Infective  

  • Europe  


View report >

Therapy and Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Therapy  


  • Europe  


View report >

Opioid and Therapy Market in the US

  • October 2016
    13 pages
  • Opioid  


  • United States  

View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.